119 related articles for article (PubMed ID: 9354689)
1. IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture.
Rivkin G; Link G; Simhon E; Cyjon RL; Klein JY; Hershko C
Blood; 1997 Nov; 90(10):4180-7. PubMed ID: 9354689
[TBL] [Abstract][Full Text] [Related]
2. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
3. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
Zevin S; Link G; Grady RW; Hider RC; Peter HH; Hershko C
Blood; 1992 Jan; 79(1):248-53. PubMed ID: 1728313
[TBL] [Abstract][Full Text] [Related]
4. Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats.
Hershko C
Blood; 1978 Mar; 51(3):415-23. PubMed ID: 623907
[TBL] [Abstract][Full Text] [Related]
5. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts.
Green R; Miller J; Crosby W
Blood; 1981 May; 57(5):866-72. PubMed ID: 7214016
[TBL] [Abstract][Full Text] [Related]
7. A rapid assay for evaluation of iron-chelating agents in rats.
Pippard MJ; Johnson DK; Finch CA
Blood; 1981 Oct; 58(4):685-92. PubMed ID: 7272500
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
Hershko C; Grady RW; Cerami A
J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte iron kinetics in the rat explored with an iron chelator.
Pippard MJ; Johnson DK; Finch CA
Br J Haematol; 1982 Oct; 52(2):211-24. PubMed ID: 7126464
[TBL] [Abstract][Full Text] [Related]
10. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
Lau EH; Cerny EA; Wright BJ; Rahman YE
J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
[TBL] [Abstract][Full Text] [Related]
11. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
Corden BJ
Exp Hematol; 1986 Nov; 14(10):971-4. PubMed ID: 3770104
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated desferrioxamine in experimental iron overload.
Lau EH; Cerny EA; Rahman YE
Br J Haematol; 1981 Apr; 47(4):505-18. PubMed ID: 7213574
[TBL] [Abstract][Full Text] [Related]
13. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone.
Cikrt M; Ponka P; Necas E; Neuwirt J
Br J Haematol; 1980 Jun; 45(2):275-83. PubMed ID: 7437326
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization.
Laub R; Schneider YJ; Octave JN; Trouet A; Crichton RR
Biochem Pharmacol; 1985 Apr; 34(8):1175-83. PubMed ID: 3994740
[TBL] [Abstract][Full Text] [Related]
15. Storage iron kinetics. 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells.
Hershko C; Cook JD; Finch DA
J Lab Clin Med; 1973 Jun; 81(6):876-86. PubMed ID: 4196982
[No Abstract] [Full Text] [Related]
16. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
Hershko C; Grady RW; Link G
Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.
Link G; Ponka P; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
Blood; 2003 May; 101(10):4172-9. PubMed ID: 12511418
[TBL] [Abstract][Full Text] [Related]
18. Deferoxamine inhibition of malaria is independent of host iron status.
Hershko C; Peto TE
J Exp Med; 1988 Jul; 168(1):375-87. PubMed ID: 3294334
[TBL] [Abstract][Full Text] [Related]
19. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation.
Fillet G; Beguin Y; Baldelli L
Blood; 1989 Aug; 74(2):844-51. PubMed ID: 2502204
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
Hershko C; Grady RW; Link G
Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
